Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Deletion of Vhlh in chondrocytes reduces cell proliferation and increases matrix deposition during growth plate development.

Pfander D, Kobayashi T, Knight MC, Zelzer E, Chan DA, Olsen BR, Giaccia AJ, Johnson RS, Haase VH, Schipani E.

Development. 2004 May;131(10):2497-508.

PMID:
15128677
[PubMed - indexed for MEDLINE]
Free Article
2.

Vhlh gene deletion induces Hif-1-mediated cell death in thymocytes.

Biju MP, Neumann AK, Bensinger SJ, Johnson RS, Turka LA, Haase VH.

Mol Cell Biol. 2004 Oct;24(20):9038-47.

PMID:
15456877
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Loss of VHL in mesenchymal progenitors of the limb bud alters multiple steps of endochondral bone development.

Mangiavini L, Merceron C, Araldi E, Khatri R, Gerard-O'Riley R, Wilson TL, Rankin EB, Giaccia AJ, Schipani E.

Dev Biol. 2014 Sep 1;393(1):124-36. doi: 10.1016/j.ydbio.2014.06.013. Epub 2014 Jun 24.

PMID:
24972088
[PubMed - indexed for MEDLINE]
4.

Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival.

Schipani E, Ryan HE, Didrickson S, Kobayashi T, Knight M, Johnson RS.

Genes Dev. 2001 Nov 1;15(21):2865-76.

PMID:
11691837
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Regression of solid tumors by engineered overexpression of von Hippel-Lindau tumor suppressor protein and antisense hypoxia-inducible factor-1alpha.

Sun X, Kanwar JR, Leung E, Vale M, Krissansen GW.

Gene Ther. 2003 Dec;10(25):2081-9.

PMID:
14595381
[PubMed - indexed for MEDLINE]
6.

pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development.

Stickle NH, Chung J, Klco JM, Hill RP, Kaelin WG Jr, Ohh M.

Mol Cell Biol. 2004 Apr;24(8):3251-61.

PMID:
15060148
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Hypoxia and HIF-1alpha in chondrogenesis.

Schipani E.

Ann N Y Acad Sci. 2006 Apr;1068:66-73. Review.

PMID:
16831906
[PubMed - indexed for MEDLINE]
8.

Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.

Miller F, Kentsis A, Osman R, Pan ZQ.

J Biol Chem. 2005 Mar 4;280(9):7985-96. Epub 2004 Dec 20.

PMID:
15611064
[PubMed - indexed for MEDLINE]
Free Article
9.

Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.

Zimmer M, Doucette D, Siddiqui N, Iliopoulos O.

Mol Cancer Res. 2004 Feb;2(2):89-95.

PMID:
14985465
[PubMed - indexed for MEDLINE]
Free Article
10.

Runx2 protein stabilizes hypoxia-inducible factor-1α through competition with von Hippel-Lindau protein (pVHL) and stimulates angiogenesis in growth plate hypertrophic chondrocytes.

Lee SH, Che X, Jeong JH, Choi JY, Lee YJ, Lee YH, Bae SC, Lee YM.

J Biol Chem. 2012 Apr 27;287(18):14760-71. doi: 10.1074/jbc.M112.340232. Epub 2012 Feb 20.

PMID:
22351759
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Identification of novel VHL target genes and relationship to hypoxic response pathways.

Maina EN, Morris MR, Zatyka M, Raval RR, Banks RE, Richards FM, Johnson CM, Maher ER.

Oncogene. 2005 Jun 30;24(28):4549-58.

PMID:
15824735
[PubMed - indexed for MEDLINE]
12.

von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.

Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG Jr.

Hum Mol Genet. 2001 May 1;10(10):1019-27.

PMID:
11331612
[PubMed - indexed for MEDLINE]
Free Article
13.

Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.

Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER.

Cancer Res. 2002 Jul 1;62(13):3803-11.

PMID:
12097293
[PubMed - indexed for MEDLINE]
Free Article
14.

The von Hippel-Lindau tumor suppressor gene.

Kondo K, Kaelin WG Jr.

Exp Cell Res. 2001 Mar 10;264(1):117-25. Review.

PMID:
11237528
[PubMed - indexed for MEDLINE]
15.

Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein.

Corn PG, McDonald ER 3rd, Herman JG, El-Deiry WS.

Nat Genet. 2003 Nov;35(3):229-37. Epub 2003 Oct 12.

PMID:
14556007
[PubMed - indexed for MEDLINE]
16.

Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells.

Gunaratnam L, Morley M, Franovic A, de Paulsen N, Mekhail K, Parolin DA, Nakamura E, Lorimer IA, Lee S.

J Biol Chem. 2003 Nov 7;278(45):44966-74. Epub 2003 Aug 27.

PMID:
12944410
[PubMed - indexed for MEDLINE]
Free Article
17.
18.

Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.

Baba M, Hirai S, Yamada-Okabe H, Hamada K, Tabuchi H, Kobayashi K, Kondo K, Yoshida M, Yamashita A, Kishida T, Nakaigawa N, Nagashima Y, Kubota Y, Yao M, Ohno S.

Oncogene. 2003 May 8;22(18):2728-38.

PMID:
12743597
[PubMed - indexed for MEDLINE]
19.

Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain.

Lolkema MP, Gervais ML, Snijckers CM, Hill RP, Giles RH, Voest EE, Ohh M.

J Biol Chem. 2005 Jun 10;280(23):22205-11. Epub 2005 Apr 11.

PMID:
15824109
[PubMed - indexed for MEDLINE]
Free Article
20.

Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation.

He Z, Liu S, Guo M, Mao J, Hughson MD.

Cancer Genet Cytogenet. 2004 Jul 15;152(2):89-94.

PMID:
15262424
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk